Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Researchers search for SARS-CoV-2 fomites on an operational Italian bus

A new study reports the results of a viral detection study carried out in buses used for public transport across the final week of lockdown, as travel restrictions were being lifted step by step. This study by Italian researchers and published on the preprint server bioRxiv* in June 2020, may help to understand how a virus can spread within a city bus during normal operation and how effective are the measures used to protect against such transmission.

30 Jun 2020

Identification of SARS-CoV-2 RNA in healthcare HVAC units

Now, a new study published on the preprint server medRxiv* in June 2020 reports that viral RNA has been found to occur in HVAC (Heating, Ventilation, and AC) units in healthcare facilities. However, it is not clear if this represents a possible mechanism of viral transmission.

30 Jun 2020

Modified Vaccinia Ankara-based vaccine candidate for SARS-CoV-2

Now, a new study by researchers at Emory University, the University of Texas Medical Branch and the Ragon Institute and published on the preprint server bioRxiv in June 2020 reports the development of a promising new vaccine candidate that may rapidly and effectively induce the production of neutralizing antibodies against the spike protein of the virus.

30 Jun 2020

China imposes lockdowns as new coronavirus cases surge

The coronavirus disease (COVID-19) pandemic first emerged in a seafood market in Wuhan City, Hubei Province, China, in December 2019. Since then, it has spread to 188 countries and territories and infected more than 10 million people. The viral infection has so far killed more than 500,000 people worldwide.

29 Jun 2020

COVID-19 survivors should be screened for PTSD, experts warn

Contracting the coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be a stressful and traumatic experience. Patients who became seriously ill with the viral infection should be screened for post-traumatic stress disorder (PTSD) due to their experiences in fighting for their lives, mental health experts recommended.

29 Jun 2020

WHO says worst is yet to come as COVID-19 pandemic speeds up

The true number of global infections and deaths, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is likely to be significantly higher due to lack of testing. Some people are also asymptomatic, which means they had no symptoms of the illness.

29 Jun 2020

A glycan analysis of SARS-CoV-2 ACE2 complex

Researchers in the U.S. have produced molecular dynamic simulations of the Spike protein found on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its interaction with the host cell receptor angiotensin-converting enzyme 2 (ACE2).

29 Jun 2020

Stanford's Nobel Laureate develops a prediction model for SARS-CoV-2

The researchers from Stanford School of Medicine and ShangaiTech University show that the growth of a coronavirus disease (COVID-19) outbreak does not behave in accordance with an exponential growth law, but instead slows down exponentially with time from the very first days. Their thought-provoking findings can be currently found in the medRxiv* preprint server.

29 Jun 2020

SARS-CoV-2 circulating in Italy in December 2019

Researchers at the Istituto Superiore di Sanità (Italian National Institute of Health) have shown that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had already been circulating in Italy many weeks before the first autochthonous (native) case was documented on February 21st this year.

29 Jun 2020

Virus re-emergence after lockdown ends

A new report in the journal Nature Human Behaviour in June 2020 reports predictions as to the effects of removing lockdown restrictions on the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and suggests that individual responsibility concerning social distancing and other precautions could avoid the need for lockdowns.

28 Jun 2020

Similarities between coronaviruses and human genes promote infection

A new study published on the preprint server bioRxiv* in June 2020 shows that the proportion of A/T pairing in viral genomes may increase the tendency to infect humans because of the matching molecular features in some host genes, that increases the susceptibility of the host to the virus.

28 Jun 2020

Genomics used to trace origin of SARS-CoV-2 in Canada

A new study published in June 2020 on the preprint server bioRxiv discusses the use of phylogenetic analysis to trace the origin of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and its spread into and then within Canada. The study findings may help optimize public health policies in the case of future outbreaks.

28 Jun 2020

Study identifies small molecule inhibitors of SARS-CoV-2 which block key cellular kinases

Antiviral drug screen of kinase inhibitors, which was done by researchers from the University of California and Cedars-Sinai Medical Center, identified cellular signaling pathways critical for SARS-CoV-2 replication and revealed an important mechanism of host-pathogen interaction vital for further drug research. Their results are available on the bioRxiv* preprint server.

28 Jun 2020

Mathematical model reveals the risk of SARS-CoV-2 infection after fecal microbiota transplantation

In their new paper available on the bioRxiv* preprint server, US researchers from the OpenBiome nonprofit organization used a mathematical model to simulate the usefulness of different testing strategies for fecal samples and showed that the probability of releasing a fecal microbiota donation with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is low when several important variables are taken into account.

28 Jun 2020

Antibody tests may give false hope of immunity, health experts warn

Amid the coronavirus pandemic, health experts warn against the use of antibody tests to determine if a person has immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). An antibody test determines if a person developed antibodies against the infection due to past exposure.

26 Jun 2020

China to initiate phase 3 SARS-CoV-2 vaccine trial in UAE

Now, China is ready to run its large-scale phase III clinical trial of its novel coronavirus candidate in the United Arab Emirates (UAE). Over a dozen experimental vaccines are being trialed across the globe, but China’s vaccine is the first one to proceed to phase III human trials.

26 Jun 2020

Chilblains and COVID-19

The current COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is primarily a respiratory infection, though the majority of cases are asymptomatic or mild disease. However, other manifestations are also being reported, such as gastrointestinal features, neurological signs, and skin symptoms. A new study published online in the journal JAMA Dermatology in June 2020 examines the possibility that chilblains could be a manifestation of COVID-19.

26 Jun 2020

Genes associated with SARS-CoV-2 human lung cell infection

Now, a new study published on the preprint server bioRxiv in June 2020 attempts to make sense of this data to identify viral genes that are explicitly expressed in the cells infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This could help reveal new therapeutic targets.

26 Jun 2020

SARS-CoV-2 has been evolving for at least 7 years

The burning question is how novel viruses acquire the ability to recognize, bind to and enter human cells for the first time – whether this is dependent only on viral proteins recognizing host cell proteins, or adaptations in other viral processes that allow replication in a human host.

25 Jun 2020

Pixatimod is active in lab studies against SARS-CoV-2

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) circulating the world has caused over 9.6 million cases and over 490,000 deaths as of June 26, 2020. With neither an effective vaccine nor therapeutic drug yet available, intensive and widespread research is ongoing to develop a pharmacological intervention that will halt the global pandemic.

25 Jun 2020